Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06517875 · ClinicalTrials.gov registry record · Phase 2
Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
A Phase 2 study of Primary Myelofibrosis and Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis, sponsored by GlaxoSmithKline.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
- 14
- Study locations
NCT06517875 is a Phase 2 study of Primary Myelofibrosis and Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis that is actively recruiting participants, run by GlaxoSmithKline. The registered enrollment target is 56 participants, below the 119-participant average among 30 other Primary Myelofibrosis trials with a reported enrollment target (53% lower). The trial reports 14 study locations across 4 states.
The verdict
NCT06517875, a Phase 2 study of Primary Myelofibrosis and Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis, is actively recruiting participants, sponsored by GlaxoSmithKline.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
- 14
- Study locations
Study Summary
The purpose of this Phase 2 study is to evaluate the efficacy and safety of momelotinib (MMB) in combination with luspatercept (LUSPA) in participants with transfusion dependence (TD) primary myelofibrosis (PMF) or Post-polycythemia vera (PV)/ essential thrombocythemia (ET) myelofibrosis (MF) who are either janus kinase (JAK) inhibitor (JAKi) naïve or experienced.
Conditions Studied
Interventions
- DRUG Luspatercept
- DRUG Momelotinib
Study Locations (14)
Other
- GSK Investigational Site - Angers
- GSK Investigational Site - Brest
- GSK Investigational Site - Lyon
- GSK Investigational Site - Nice
- GSK Investigational Site - Nîmes
- GSK Investigational Site - Paris
- GSK Investigational Site - Poitiers
- GSK Investigational Site - Florence
- GSK Investigational Site - Roma
- GSK Investigational Site - Málaga
- GSK Investigational Site - Valencia
Tennessee
- GSK Investigational Site - Nashville
Ontario
- GSK Investigational Site - Toronto
Quebec
- GSK Investigational Site - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2025-02-28 |
| Est. Completion | 2026-11-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06517875
The ClinicalTrials.gov registry entry for NCT06517875 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 119-participant average among 30 other Primary Myelofibrosis trials with a reported enrollment target (53% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Primary Myelofibrosis appearing as the primary indexed condition, and to 2 interventions - of which Luspatercept is the first listed.
NCT06517875 reports 14 study locations spanning 4 distinct geographic areas - top geographies include Other, Tennessee, Ontario.
Frequently Asked Questions
What is clinical trial NCT06517875 about?
NCT06517875 is a clinical study titled "Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis". The purpose of this Phase 2 study is to evaluate the efficacy and safety of momelotinib (MMB) in combination with luspatercept (LUSPA) in participants with transfusion dependence (TD) primary myelofibrosis (PMF) or Post-polycythemia vera (PV)/ essential thrombocythemia (ET) myelofibrosis (MF) who ar...
What is the current status of trial NCT06517875?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2025-02-28. Estimated completion is 2026-11-13.
What conditions does trial NCT06517875 study?
This clinical trial studies the following conditions: Primary Myelofibrosis, Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis.
What interventions are being tested in trial NCT06517875?
The interventions under investigation include: Luspatercept (DRUG), Momelotinib (DRUG).
Who is sponsoring clinical trial NCT06517875?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06517875 being conducted?
This trial has 14 study locations across Tennessee, Ontario, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Myelofibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis
RECRUITING · Phase 2
-
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
RECRUITING · Phase 2
-
Study of Canakinumab in Patients With Myelofibrosis
RECRUITING · Phase 2
-
Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes
RECRUITING · Phase 2
-
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
RECRUITING · Phase 2
-
Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Primary Myelofibrosis
All registered trials for this condition
Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
All registered trials for this condition
Tennessee
All trials with a study site in Tennessee
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.